Patrick Zakka, MD

DocwireNews

Insomnia has been associated with worse outcomes in patients with chronic obstructive pulmonary disease (CPOD); however, the impact of concurrent insomnia on healthcare utilization and costs related to COPD is unknown, according to a study by Faith S. Luyster and colleagues.
After their investigation, the researchers reported insomnia was associated with increased outpatient visits, hospitalizations, fills for corticosteroids and antibiotics, hospitalization lengths, and hospitalization costs within 12 months of insomnia diagnoses in patients with COPD. The data were published in Respiratory Research.
<h3>Insomnia Worsens 1-Year Utilization and Cost Outcomes</h3>
The study’s authors enrolled a retrospective cohort of veterans with COPD from the national Veterans Affairs administration database from 2012 to 2017. Insomnia was defined as an <a href="https://www.docwirenews.com/docwire-pick/neurology/clozapine-versus-other-antipsychotics-for-insomnia-in-schizophrenia/">insomnia</a> diagnosis or a prescription of over 30 doses of a sedative-hypnotic medication within 1 fiscal year.
The primary end points of the study were resource utilization and costs related to outpatient visits and hospitalizations within 1 year of indexing. Patients without insomnia had their COPD-related resource utilization estimated based on prescription fills of corticosteroids and antibiotics, and outpatient visits or hospitalizations with a primary diagnosis of COPD.
According to the authors, out of 1,011,646 patients with COPD (96% male; mean years of age, 68.4), 407,363 (38.8%) had insomnia. After adjusting for confounders, insomnia was associated with $10,344 higher hospitalization costs in the 12 months following the first date criteria for both insomnia and COPD were met.
Overall, the authors concluded that “these findings highlight the importance of insomnia as a potentially modifiable target for reducing the burden of COPD on patients and healthcare systems.”
Related: <a href="https://www.docwirenews.com/docwire-pick/daridorexant-for-insomnia-long-term-findings/">Daridorexant for Insomnia: Long-Term Findings </a>

Insomnia has been associated with worse outcomes in patients with chronic obstructive pulmonary disease (CPOD); however, the impact of concurrent insomnia on healthcare utilization and costs related to COPD is unknown, according to a study by Faith S. Luyster and colleagues.After their investigation, the researchers reported insomnia was associated with increased outpatient visits, hospitalizations, fills for corticosteroids and antibiotics, hospitalization lengths, and hospitalization costs within 12 months of insomnia diagnoses in patients with COPD. The data were published in Respiratory Research.<h3>Insomnia Worsens 1-Year Utilization and Cost Outcomes</h3>The study’s authors enrolled a retrospective cohort of veterans with COPD from the national Veterans Affairs administration database from 2012 to 2017. Insomnia was defined as an <a href="https://www.docwirenews.com/docwire-pick/neurology/clozapine-versus-other-antipsychotics-for-insomnia-in-schizophrenia/">insomnia</a> diagnosis or a prescription of over 30 doses of a sedative-hypnotic medication within 1 fiscal year.The primary end points of the study were resource utilization and costs related to outpatient visits and hospitalizations within 1 year of indexing. Patients without insomnia had their COPD-related resource utilization estimated based on prescription fills of corticosteroids and antibiotics, and outpatient visits or hospitalizations with a primary diagnosis of COPD.According to the authors, out of 1,011,646 patients with COPD (96% male; mean years of age, 68.4), 407,363 (38.8%) had insomnia. After adjusting for confounders, insomnia was associated with $10,344 higher hospitalization costs in the 12 months following the first date criteria for both insomnia and COPD were met.Overall, the authors concluded that “these findings highlight the importance of insomnia as a potentially modifiable target for reducing the burden of COPD on patients and healthcare systems.”Related: <a href="https://www.docwirenews.com/docwire-pick/daridorexant-for-insomnia-long-term-findings/">Daridorexant for Insomnia: Long-Term Findings </a>

Lauren Dembeck, PhD

AI Decodes Herbal Remedies for Cough-Variant Asthma

Asthma

Strategies for Managing Colorectal Polyps and Cancer Risk

Colon Polyps

Two Decades of IBS Tweets Offer Insight Into Patient Experience and Care Priorities

Latest News

Characterizing Insomnia's Impact on COPD Care

Neurology

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe